secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2023-10-30T23:59:59+00:00
Accession:  0000950170-23-056335
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomea Fusion reports Q3 net loss of $28.4M, advances diabetes and oncology pipeline
--------------------------------------------------------------------------------

- Net loss of $28.4M for Q3 2023 vs $22.9M in Q3 2022; cash of $199.5M as of Sep 30, 2023.
- COVALENT-111 expansion cleared; 84% of patients showed HbA1c reduction at Week 4; enrollment in ~200 type 2 diabetics.
- IND cleared for COVALENT-112 (BMF-219) in type 1 diabetes; enrollment of 150 adults expected to start in Q4 2023.
- Initial AML data: 2 CRs out of 5 patients with menin-dependent mutations at Dose Level 4; BMF-500 first patient dosed.
- Appointed Juan Pablo Frías, M.D., as Chief Medical Officer to oversee diabetes clinical development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000095017023056335/0000950170-23-056335-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000095017023056335/bmea-20231030.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-056335

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer